|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1990-8-23
|
|
pubmed:abstractText |
Carmustine (BCNU) is an anticancer drug known to produce pulmonary fibrosis as a side effect within three years of treatment. It is not known whether pulmonary fibrosis can appear later.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0028-4793
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
9
|
|
pubmed:volume |
323
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
378-82
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:2370889-Acute Disease,
pubmed-meshheading:2370889-Adolescent,
pubmed-meshheading:2370889-Brain Neoplasms,
pubmed-meshheading:2370889-Carmustine,
pubmed-meshheading:2370889-Child,
pubmed-meshheading:2370889-Female,
pubmed-meshheading:2370889-Humans,
pubmed-meshheading:2370889-Lung,
pubmed-meshheading:2370889-Male,
pubmed-meshheading:2370889-Pulmonary Fibrosis,
pubmed-meshheading:2370889-Radiography, Thoracic,
pubmed-meshheading:2370889-Spirometry,
pubmed-meshheading:2370889-Time Factors,
pubmed-meshheading:2370889-Tomography, X-Ray Computed,
pubmed-meshheading:2370889-Vital Capacity
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
|
|
pubmed:affiliation |
Northwest Regional Cardiothoracic Unit, Wythenshawe Hospital, Manchester, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
